JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
MADISON, Wis. - Exact Sciences Corp. (NASDAQ:EXAS), currently trading at $51.91 with a market capitalization of $9.8 billion, will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025, according to a company press release. InvestingPro analysis indicates the stock is currently undervalued, with three analysts recently revising earnings expectations upward.
Following the release, management will host a webcast and conference call at 5 p.m. ET to discuss the quarterly financial performance and business developments.
Investors and other interested parties can access the live webcast through the company’s website. For those preferring to join by telephone, domestic callers may dial 888-330-2384, while international participants should call +1 240-789-2701. Both domestic and international callers will need to use access code 4437608.
A replay of the webcast will be available on the company’s website following the live event.
Exact Sciences, which provides cancer screening and diagnostic tests, offers products including Cologuard and Oncotype DX. The company focuses on developing technologies to assist healthcare providers and patients with cancer-related decisions.
The announcement was made in a press release issued by the company.
In other recent news, Exact Sciences Corporation reported its first-quarter 2025 earnings, revealing a revenue of $707 million, surpassing analyst expectations of $688.78 million. However, the company’s earnings per share (EPS) showed a deeper loss of $0.54 compared to the anticipated loss of $0.33. In a separate development, Exact Sciences announced that its Oncodetect molecular residual disease test received Medicare coverage, a significant milestone that unlocks long-term growth potential in the molecular residual disease market. This Medicare coverage applies to patients with stage II, III, and resectable stage IV colorectal cancer for a five-year period. Analyst firms Canaccord Genuity and Raymond James responded positively to these developments, with Canaccord maintaining a Buy rating and Raymond James upgrading the stock to Market Perform. Additionally, Exact Sciences’ shareholders approved the 2025 Omnibus Long-Term Incentive Plan and an amendment to the Employee Stock Purchase Plan during the annual meeting. These recent developments reflect strategic moves by Exact Sciences to solidify its market position and expand its product offerings in cancer diagnostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.